• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Jalyn (dutasteride and tamsulosin HCL) capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2012

 

Summary View

 

WARNINGS and PRECAUTIONS

Evaluation for Other Urological Diseases
  • Prior to initiating treatment with Jalyn, consideration should be given to other urological conditions that may cause similar symptoms. In addition, BPH and prostate cancer may coexist.